secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0001564590-21-056478
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics Q3 loss widens to $30.7M; CFO and CMO depart; cash $320.9M
-------------------------------------------------------------------------------

- Q3 net loss $30.7M ($0.66/sh) vs $16.8M loss in Q3 2020; cash, equivalents and securities $320.9M.
- CFO Brian Piper resigns effective Nov 19; Laurent Chardonnet appointed CFO from Nov 29.
- CMO Dr. David Mauro mutually agreed to depart Nov 9; search for successor ongoing.
- PRT2527 IND cleared; Phase 1 trial to start by year-end; PRT543/811 expansion data expected in 2022.
- Retention bonus of $200k approved for EVP Deborah Morosini if employed through Nov 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000156459021056478/0001564590-21-056478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000156459021056478/prld-8k_20211105.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-056478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer